Crescita Therapeutics Inc.
CTX.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 20.53% | -223.47% | -130.08% | -112.71% | -739.33% |
| Total Depreciation and Amortization | -18.61% | -20.39% | 2.99% | 0.32% | 2.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.65% | -72.92% | -140.87% | 206.92% | -66.00% |
| Change in Net Operating Assets | 3.83% | 431.46% | -62.06% | 74.26% | 435.60% |
| Cash from Operations | 233.58% | 562.85% | -82.20% | 88.25% | -73.33% |
| Capital Expenditure | -2,818.66% | -- | -- | -704.17% | -1,293.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2,544.98% | -- | -- | -41.65% | -1,293.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.80% | -8.91% | -9.09% | -6.06% | -11.96% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 51.25% | -- | -- | -112.50% | -33.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 31.13% | -53.59% | -139.07% | -16.46% | -15.88% |
| Foreign Exchange rate Adjustments | -176.22% | 113.43% | -18.92% | -218.92% | -60.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -175.39% | -939.18% | -92.81% | 74.62% | -184.47% |
